Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program

Diabetes/Metabolism Research and Reviews

Volumn 32, Issue 8, 2016, Pages 776-790

  Jendle, Johan ^a   Grunberger, George ^b   Blevins, Thomas ^c   Giorgino, Francesco ^d   Hietpas, Ryan T ^e   Botros, Fady T ^e  

^a ÖREBRO UNIVERSITY   (Sweden)

^b Grunberger Diabetes Institute   (United States)

^c Texas Diabetes and Endocrinology   (United States)

^d UNIVERSITY OF BARI   (Italy)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

dulaglutide; GLP 1 receptor agonist; type 2 Diabetes

Indexed keywords

DRUG ANTIBODY; DULAGLUTIDE; EXENDIN 4; HEMOGLOBIN A1C; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; SITAGLIPTIN; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT;

ANTIBODY PRODUCTION; COMPARATIVE EFFECTIVENESS; DIABETIC PATIENT; DIARRHEA; DRUG FATALITY; DRUG SAFETY; DRUG STRUCTURE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; INSULIN TREATMENT; META ANALYSIS (TOPIC); NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VOMITING; WEIGHT CHANGE; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS, TYPE 2; SAFETY; TREATMENT OUTCOME;

ANIMALS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDES; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOGLOBULIN FC FRAGMENTS; RECOMBINANT FUSION PROTEINS; SAFETY; TREATMENT OUTCOME;

EID: 84969988486     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2810     Document Type: Review

References (60)

1. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. US Department of Health and Human Services, Centers for Disease Control and Prevention. Available at: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf. Accessed July 15, 2015.
2. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321(7258): 405–412.
3. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58(4): 773–795. doi:10.2337/db09-9028.
4. Schwartz SS. A practice-based approach to the 2012 position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Curr Med Res Opin 2013; 29(7): 793–799. doi:10.1185/03007995.2013.798637.
5. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35(6): 1364–1379. doi:10.2337/dc12-0413.
6. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38(1): 140–149. doi:10.2337/dc14-2441.
7. Inkster B, Zammitt NN, Frier BM. Drug-induced hypoglycaemia in type 2 diabetes. Expert Opin Drug Saf 2012; 11(4): 597–614. doi:10.1517/14740338.2012.694424.
8. Holst JJ, Knop FK, Vilsboll T, Krarup T, Madsbad S. Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diabetes Care 2011; 34(Suppl 2): S251–S257. doi:10.2337/dc11-s227.
9. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29(1): 46–52.
10. Ahren B. Incretin dysfunction in type 2 diabetes: clinical impact and future perspectives. Diabetes Metab 2013; 39(3): 195–201. doi:10.1016/j.diabet.2013.03.001.
11. DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care 2013; 36(Suppl 2): S127–S138.
12. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987; 2(8571): 1300–1304.
13. Ritzel R, Orskov C, Holst JJ, Nauck MA. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia 1995; 38(6): 720–725.
14. Naslund E, Gutniak M, Skogar S, Rossner S, Hellstrom PM. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. Am J Clin Nutr 1998; 68(3): 525–530.
15. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993; 38(4): 665–673.
16. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368(9548): 1696–1705.
17. Naslund E, Barkeling B, King N, et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 1999; 23(3): 304–311.
18. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87(4): 1409–1439.
19. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995; 44(9): 1126–1131.
20. Deacon CF. Circulation and degradation of GIP and GLP-1. Horm Metab Res 2004; 36(11-12): 761–765.
21. Cho YM, Wideman RD, Kieffer TJ. Clinical application of glucagon-like Peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus. Endocrinol Metab (Seoul) 2013; 28(4): 262–274. doi:10.3803/EnM.2013.28.4.262.
22. Kuritzky L, Umpierrez G, Ekoe JM, Mancillas-Adame L, Lando LF. Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes. Postgrad Med 2014; 126(6): 60–72. doi:10.3810/pgm.2014.10.2821.
23. Glaesner W, Vick AM, Millican R, et al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev 2010; 26(4): 287–296. doi:10.1002/dmrr.1080.
24. Barrington P, Chien JY, Tibaldi F, Showalter HD, Schneck K, Ellis B. LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects. Diabetes Obes Metab 2011; 13(5): 434–438. doi:10.1111/j.1463-1326.2011.01365.x.
25. Barrington P, Chien JY, Showalter HD, et al. A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes. Diabetes Obes Metab 2011; 13(5): 426–433. doi:10.1111/j.1463-1326.2011.01364.x.
26. Peña A, Loghin C, Cui X, et al. Pharmacokinetics of Once Weekly Dulaglutide in Patients with Type 2 Diabetes Mellitus. American Diabetes Association–74th Annual Scientific Sessions. Diabetes 2014; 63(Suppl 1): A251.
27. Loghin C, Peña A, Cui X, Zhang X, Geiser J, Chien Y. Pharmacokinetics of Once Weekly Dulaglutide in Special Populations. American Diabetes Association–74th Annual Scientific Sessions. Diabetes 2014; 63(Suppl 1): A251.
28. Trulicity. [US Prescribing Information]. Houten, The Netherlands: Eli Lilly and Company; 2015.
29. Grunberger G, Chang A, Garcia Soria G, Botros FT, Bsharat R, Milicevic Z. Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study. Diabet Med 2012; 29: 1260–1267. doi:10.1111/j.1464-5491.2012.03745.x.
30. Umpierrez GE, Blevins T, Rosenstock J, Cheng C, Anderson JH, Bastyr EJ 3rd. The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study. Diabetes Obes Metab 2011; 13(5): 418–425. doi:10.1111/j.1463-1326.2011.01366.x.
31. Terauchi Y, Satoi Y, Takeuchi M, Imaoka T. Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study. Endocr J 2014; 61(10): 949–959.
32. Ferdinand KC, White WB, Calhoun DA, et al. Effects of the once-weekly glucagon-like Peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension 2014; 64(4): 731–737. doi:10.1161/HYPERTENSIONAHA.114.03062.
33. Skrivanek Z, Gaydos BL, Chien JY, et al. Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5). Diabetes Obes Metab 2014; 16(8): 748–756. doi:10.1111/dom.12305.
34. Umpierrez G, Tofe Povedano S, Perez Manghi F, Shurzinske L, Pechtner V. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care 2014; 37(8): 2168–2176. doi:10.2337/dc13-2759.
35. Wysham C, Blevins T, Arakaki R, et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care 2014; 37(8): 2159–2167. doi:10.2337/dc13-2760.
36. Blonde L, Jendle J, Gross J, et al. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Lancet 2015; 385(9982): 2057–2066. doi:10.1016/S0140-6736(15)60936-9.
37. Weinstock RS, Guerci B, Umpierrez G, Nauck MA, Skrivanek Z, Milicevic Z. Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study. Diabetes Obes Metab 2015; 17(9): 849–858. doi:10.1111/dom.12479.
38. Giorgino F, Benroubi M, Sun JH, Zimmermann AG, Pechtner V. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care 2015; 38(12): 2241–2249. doi:10.2337/dc14-1625.
39. Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet 2014; 384(9951): 1349–1357. doi:10.1016/S0140-6736(14)60976-4.
40. Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care 2014; 37(8): 2149–2158. doi:10.2337/dc13-2761.
41. Trulicity. [Summary of Product Characteristics]. Houten, The Netherlands: Eli Lilly and Company; 2015.
42. Ferdinand KC, Sager P, Atisso C, Botros FT. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events. Cardiovasc Diabetol 2016; 15(1): 38. doi:10.1186/s12933-016-0355-z.
43. Milicevic Z, Anglin G, Harper K, et al. Low incidence of anti-drug antibodies in type 2 diabetes patients treated with once weekly GLP-1 receptor agonist dulaglutide. Diabetes Obes Metab 2016; [Epub ahead of print]. doi:. doi:10.1111/dom.12640.
44. American Diabetes Association. Strategies for improving care. In standards of medical care in diabetes - 2015. Diabetes Care 2015; 38(Suppl. 1): S1–S92. doi:10.2337/dc15-S001.
45. Garber AJ, Abrahamson MJ, Barzilay JI, et al. American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement–executive summary. Endocr Pract 2013; 19(3): 536–557. doi:10.4158/EP13176.CS.
46. Matfin G, Van Brunt K, Zimmermann AG, Threlkeld R, Ignaut DA. Safe and effective use of the once weekly dulaglutide single-dose Pen in injection-naïve patients with type 2 diabetes. J Diabetes Sci Technol 2015; 9(5): 1071–1079. doi:10.1177/1932296815583059.
47. Mann KV, Raskin P. Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes. Diabetes Metab Syndr Obes 2014; 7: 229–239. doi:10.2147/DMSO.S35331.
48. van Bloemendaal L, Ten Kulve JS, la Fleur SE, Ijzerman RG, Diamant M. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol 2014; 221(1): T1–T16. doi:10.1530/JOE-13-0414.
49. Trujillo JM, Nuffer W. Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Ann Pharmacother 2014; 48(11): 1494–1501. doi:10.1177/1060028014545807.
50. Rigato M, Fadini GP. Comparative effectiveness of liraglutide in the treatment of type 2 diabetes. Diabetes Metab Syndr Obes 2014; 7: 107–120. doi:10.2147/DMSO.S37644.
51. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373(9662): 473–481. doi:10.1016/S0140-6736(08)61246-5.
52. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009; 32(1): 84–90. doi:10.2337/dc08-1355.
53. Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010; 375(9733): 2234–2243. doi:10.1016/S0140-6736(10)60406-0.
54. Lando HM, Alattar M, Dua AP. Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting. Endocr Pract 2012; 18(4): 472–477. doi:10.4158/EP11290.OR.
55. Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011; 96(5): 1301–1310. doi:10.1210/jc.2010-2081.
56. DeVries JH, Bain SC, Rodbard HW, et al. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. Diabetes Care 2012; 35(7): 1446–1454. doi:10.2337/dc11-1928.
57. Robinson LE, Holt TA, Rees K, Randeva HS, O'Hare JP. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open 2013; 3(1): pii:e001986. doi:10.1136/bmjopen-2012-001986.
58. López-Ruiz A, del Peso-Gilsanz C, Meoro-Avilés A, et al. Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers. Pharm World Sci 2010; 32(5): 559–561. doi:10.1007/s11096-010-9423-8.
59. Weise WJ, Sivanandy MS, Block CA, Comi RJ. Exenatide-associated ischemic renal failure. Diabetes Care 2009; 32(2): c22–c23. doi:10.2337/dc08-1309.
60. Kaakeh Y, Kanjee S, Boone K, Sutton J. Liraglutide-induced acute kidney injury. Pharmacotherapy 2012; 32(1): e7–e11. doi:10.1002/PHAR.1014.